Educational links

Medscape

To view the CME, MedScape requires visitors to create a free account.

1. Hypogonadism and cardiovascular and metabolic health: should we consider testosterone replacement?

Test-and-teach 

This activity is intended to improve physicians’ knowledge regarding the recent clinical data on the benefits of testosterone replacement in hypogonadic men with various comorbid conditions, best practice for the accurate detection and diagnosis of male hypogonadism, and optimal treatment strategies for men with hypogonadism.

    Experts

    Geoffrey_Hackett

    Geoffrey Hackett, MD, FRCPI, MRCGP

    Professor of Sexual Medicine, Aston University Birmingham;
    Consultant in Urology and Sexual Medicine, University Hospitals Birmingham;
    Birmingham, United Kingdom

    Learning objectives

    Upon completion of this activity, participants will be able to:

    Have increased knowledge of:
    Hypogonadism in men and its impact on overall health and wellbeing.
    Recent clinical data on the benefits of testosterone replacement in hypogonadic men with various comorbid conditions.
    Demonstrate greater competence in their ability to:
    Accurately detect and diagnose male hypogonadism.
    Employ best practice in the safe and effective treatment of men with hypogonadism.

    Target audience

    This educational activity is intended for an international audience of non-US healthcare professionals, speci­fically diabetologists and endocrinologists, urologists, and primary care physicians involved in the management of patients with, or at risk for, hypogonadism.

    Further information

    (PDF format)

    2. New perspectives on hypogonadism and testosterone replacement in clinical practice

    Expert column 

    The goals of this activity are to help participants identify patients with hypogonadism; provide an overview of the impact of the condition on quality of life and mortality; and review the role of testosterone replacement therapy in prostate, metabolic, and cardiovascular health.

      Experts

      Alvaro Morales

      Alvaro Morales, MD, FRCSC, FACS

      Professor Emeritus, Department of Urology, School of Medicine,
      Queen's University, Kingston,
      Ontario, Canada

      Abraham Morgentaler

      Abraham Morgentaler, MD, FACS

      Founder and Director, Men's Health Boston;
      Associate Clinical Professor of Surgery (Urology),
      Beth Israel Deaconess Medical Center and Harvard Medical School,
      Boston, United States

      Geoffrey_Hackett

      Geoffrey Hackett, MD, FRCPI, MRCGP

      Professor of Sexual Medicine, Aston University Birmingham;
      Consultant in Urology and Sexual Medicine, University Hospitals Birmingham;
      Birmingham, United Kingdom

      Michael Zitzmann

      Michael Zitzmann, MD, PhD

      Professor of Medicine, Endocrinologist, Andrologist, Diabetologist;
      Sexual Medicine (FECSM); Clinical Andrology,
      Centre for Reproductive Medicine and Andrology,
      Münster, Germany

      Learning objectives

      Upon completion of this activity, participants will be able to:

      Identify the clinical impact of testosterone deficiency on men's health, quality of life, and mortality
      Examine the latest clinical data on the interrelationships between hypogonadism and metabolic and cardiovascular risk factors, and between hypogonadism and prostate health
      Explain how to identify men at risk, diagnose hypogonadism, and how to treat and monitor patients, taking into account the latest clinical data and guidelines

      Target audience

      This educational activity is intended for an international audience of non-US healthcare professionals, speci­fically diabetologists and endocrinologists, urologists, and primary care physicians involved in the management of patients with, or at risk for, hypogonadism.

      Further information

      (PDF format)

      Medscape

      To view the CME, MedScape requires visitors to create a free account.

      Patient simulation cases

      The goal of this activity is to provide guidance to clinicians who treat male patients with LUTS symptoms and comorbidities regarding appropriate clinical workup, diagnosis, and treatment options, based on clinical data and guidelines, expert opinion, and patient preference to optimize individualized patient care.

        Experts

        Alex W.

        Alex W. Pastuszak, MD, PhD

        Assistant Professor, Division of Urology,
        Department of Urology, Department of Surgery,
        University of Utah, Salt Lake City,
        Utah, United States

        Hugh Jones

        Hugh Jones, BSc, MD, FRCP

        Professor, Barnsley Hospital NHS Foundation Trust,
        University of Sheffield, Barnsley,
        South Yorkshire, United Kingdom

        Learning objectives

        Upon completion of this activity, participants will:

        Have greater competence related to -
        Diagnosing a patient with comorbid medical disorders, who also has lower urinary tract symptoms (LUTS)
        The development of individualized treatment plans based on guidelines, expert guidance, and patient preference

        Target audience

        This educational activity is intended for an international audience of urologists, primary care physicians, diabetologists and endocrinologists who practice outside of the US.

        Medscape

        To view the CME, MedScape requires visitors to create a free account.

        2. Hypogonadism and cardiovascular and metabolic health: should we consider testosterone replacement?

        Test-and-teach 

        This activity is intended to improve physicians’ knowledge regarding the recent clinical data on the benefits of testosterone replacement in hypogonadic men with various comorbid conditions, best practice for the accurate detection and diagnosis of male hypogonadism, and optimal treatment strategies for men with hypogonadism.

          Experts

          Geoffrey_Hackett

          Geoffrey Hackett, MD, FRCPI, MRCGP

          Professor of Sexual Medicine, Aston University Birmingham;
          Consultant in Urology and Sexual Medicine, University Hospitals Birmingham;
          Birmingham, United Kingdom

          Learning objectives

          Upon completion of this activity, participants will be able to:

          Have increased knowledge of:
          Hypogonadism in men and its impact on overall health and wellbeing.
          Recent clinical data on the benefits of testosterone replacement in hypogonadic men with various comorbid conditions.
          Demonstrate greater competence in their ability to:
          Accurately detect and diagnose male hypogonadism.
          Employ best practice in the safe and effective treatment of men with hypogonadism.

          Target audience

          This educational activity is intended for an international audience of non-US healthcare professionals, speci­fically diabetologists and endocrinologists, urologists, and primary care physicians involved in the management of patients with, or at risk for, hypogonadism.

          3. New perspectives on hypogonadism and testosterone replacement in clinical practice

          Expert column 

          The goals of this activity are to help participants identify patients with hypogonadism; provide an overview of the impact of the condition on quality of life and mortality; and review the role of testosterone replacement therapy in prostate, metabolic, and cardiovascular health.

            Experts

            Alvaro Morales

            Alvaro Morales, MD, FRCSC, FACS

            Professor Emeritus, Department of Urology, School of Medicine,
            Queen's University, Kingston,
            Ontario, Canada

            Abraham Morgentaler

            Abraham Morgentaler, MD, FACS

            Founder and Director, Men's Health Boston;
            Associate Clinical Professor of Surgery (Urology),
            Beth Israel Deaconess Medical Center and Harvard Medical School,
            Boston, United States

            Geoffrey_Hackett

            Geoffrey Hackett, MD, FRCPI, MRCGP

            Professor of Sexual Medicine, Aston University Birmingham;
            Consultant in Urology and Sexual Medicine, University Hospitals Birmingham;
            Birmingham, United Kingdom

            Michael Zitzmann

            Michael Zitzmann, MD, PhD

            Professor of Medicine, Endocrinologist, Andrologist, Diabetologist;
            Sexual Medicine (FECSM); Clinical Andrology,
            Centre for Reproductive Medicine and Andrology,
            Münster, Germany

            Learning objectives

            Upon completion of this activity, participants will be able to:

            Identify the clinical impact of testosterone deficiency on men's health, quality of life, and mortality
            Examine the latest clinical data on the interrelationships between hypogonadism and metabolic and cardiovascular risk factors, and between hypogonadism and prostate health
            Explain how to identify men at risk, diagnose hypogonadism, and how to treat and monitor patients, taking into account the latest clinical data and guidelines

            Target audience

            This educational activity is intended for an international audience of non-US healthcare professionals, speci­fically diabetologists and endocrinologists, urologists, and primary care physicians involved in the management of patients with, or at risk for, hypogonadism.

            Recommendations

            Long term therapy with Nebido®

            Download center

            • PP-NEB-ALL-0347-1|
            • PP-NEB-ALL-0357-1

            Copyright © 2019,
            Bayer AG

            This website is intended to provide information to an international audience outside the USA and UK.

            Page last modified Thu, 28/11/2019

            Bayer logo